Logo image of IMVT

IMMUNOVANT INC (IMVT) Stock Fundamental Analysis

NASDAQ:IMVT - Nasdaq - US45258J1025 - Common Stock - Currency: USD

20.91  +0.11 (+0.53%)

Premarket: 21.08 +0.17 (+0.81%)

Fundamental Rating

3

Taking everything into account, IMVT scores 3 out of 10 in our fundamental rating. IMVT was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IMVT as it has an excellent financial health rating, but there are worries on the profitability. IMVT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IMVT has reported negative net income.
IMVT had a negative operating cash flow in the past year.
IMVT had negative earnings in each of the past 5 years.
IMVT had a negative operating cash flow in each of the past 5 years.
IMVT Yearly Net Income VS EBIT VS OCF VS FCFIMVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

IMVT has a Return On Assets of -62.63%. This is in the lower half of the industry: IMVT underperforms 60.88% of its industry peers.
With a Return On Equity value of -71.93%, IMVT perfoms like the industry average, outperforming 55.22% of the companies in the same industry.
Industry RankSector Rank
ROA -62.63%
ROE -71.93%
ROIC N/A
ROA(3y)-40.43%
ROA(5y)-41.61%
ROE(3y)-44.51%
ROE(5y)-46.31%
ROIC(3y)N/A
ROIC(5y)N/A
IMVT Yearly ROA, ROE, ROICIMVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMVT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMVT Yearly Profit, Operating, Gross MarginsIMVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, IMVT has more shares outstanding
The number of shares outstanding for IMVT has been increased compared to 5 years ago.
IMVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMVT Yearly Shares OutstandingIMVT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M
IMVT Yearly Total Debt VS Total AssetsIMVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

IMVT has an Altman-Z score of 23.62. This indicates that IMVT is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of IMVT (23.62) is better than 94.34% of its industry peers.
There is no outstanding debt for IMVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.62
ROIC/WACCN/A
WACCN/A
IMVT Yearly LT Debt VS Equity VS FCFIMVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

IMVT has a Current Ratio of 7.61. This indicates that IMVT is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.61, IMVT is doing good in the industry, outperforming 70.97% of the companies in the same industry.
IMVT has a Quick Ratio of 7.61. This indicates that IMVT is financially healthy and has no problem in meeting its short term obligations.
IMVT has a better Quick ratio (7.61) than 70.97% of its industry peers.
Industry RankSector Rank
Current Ratio 7.61
Quick Ratio 7.61
IMVT Yearly Current Assets VS Current LiabilitesIMVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

IMVT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.69%.
EPS 1Y (TTM)-12.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-64.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

IMVT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.11% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-53.17%
EPS Next 2Y-28.25%
EPS Next 3Y-18.53%
EPS Next 5Y12.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMVT Yearly Revenue VS EstimatesIMVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
IMVT Yearly EPS VS EstimatesIMVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMVT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMVT Price Earnings VS Forward Price EarningsIMVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMVT Per share dataIMVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

IMVT's earnings are expected to decrease with -18.53% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.25%
EPS Next 3Y-18.53%

More info and screens

0

5. Dividend

5.1 Amount

IMVT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNOVANT INC

NASDAQ:IMVT (2/4/2025, 8:00:02 PM)

Premarket: 21.08 +0.17 (+0.81%)

20.91

+0.11 (+0.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)02-10 2025-02-10/amc
Inst Owners50.32%
Inst Owner Change-0.4%
Ins Owners1.52%
Ins Owner Change16.78%
Market Cap3.07B
Analysts88
Price Target51.65 (147.01%)
Short Float %20.62%
Short Ratio12.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.52%
Min EPS beat(2)-21.51%
Max EPS beat(2)-11.53%
EPS beat(4)1
Avg EPS beat(4)-8.59%
Min EPS beat(4)-21.51%
Max EPS beat(4)18.17%
EPS beat(8)2
Avg EPS beat(8)-10.29%
EPS beat(12)3
Avg EPS beat(12)-7.21%
EPS beat(16)5
Avg EPS beat(16)-7.14%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.94%
PT rev (3m)3.79%
EPS NQ rev (1m)-2.81%
EPS NQ rev (3m)-34.23%
EPS NY rev (1m)-0.85%
EPS NY rev (3m)-17.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.83
P/tB 6.83
EV/EBITDA N/A
EPS(TTM)-2.22
EYN/A
EPS(NY)-3.13
Fwd EYN/A
FCF(TTM)-1.86
FCFYN/A
OCF(TTM)-1.85
OCFYN/A
SpS0
BVpS3.06
TBVpS3.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.63%
ROE -71.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.43%
ROA(5y)-41.61%
ROE(3y)-44.51%
ROE(5y)-46.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 226.9%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.61
Quick Ratio 7.61
Altman-Z 23.62
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)151.14%
Cap/Depr(5y)180.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-64.44%
EPS Next Y-53.17%
EPS Next 2Y-28.25%
EPS Next 3Y-18.53%
EPS Next 5Y12.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-43.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-72.92%
EBIT Next 3Y-29.75%
EBIT Next 5YN/A
FCF growth 1Y-80.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-80.06%
OCF growth 3YN/A
OCF growth 5YN/A